Interleukin 23 (IL-23) is a member of the IL-12 family of heterodimeric cytokines, composed of p19 and p40 subunits, which exhibits immunostimulatory properties similar to IL-12. IL-23 has been shown to possess potent antitumor activities in several establishment models of cancer and a few therapeutic models, but the efficacy of local, adenoviral-mediated expression of IL-23 in established tumors has yet to be investigated. Here we have examined the antitumor activity of adenovirally delivered IL-23 in a day-7 MCA205 murine fibrosarcoma tumor model. Three intratumoral injections of adenovirus expressing IL-23 (Ad.IL-23) significantly increased animal survival and resulted in complete rejection of 40% of tumors, with subsequent generation of protective immunity and MCA205-specific cytotoxic T lymphocytes. In addition, we have shown that the antitumor activity of IL-23 is independent of IL-17, perforin and Fas ligand, but dependent on interferon-g, CD4 þ and CD8 þ T cells. These results demonstrate that direct intratumoral injection of adenovirus expressing IL-23 results in enhanced survival, tumor eradication and generation of protective immunity by generation of a Th1-type immune response.
Introduction
Interleukin 23 (IL-23) is a member of the IL-6/IL-12 family of heterodimeric cytokines and is composed of two subunits: p40, which is shared with IL-12, and p19, which is unique to IL-23. p19 is related to the p35 subunit of IL-12 and is active only when co-expressed with IL-12 p40. 1 The IL-23 receptor is composed of IL-12Rb1 and the IL-23 receptor 2 and is found in human Th0 and Th1 clones and several natural killer (NK) cell lines. 2 IL-23 is expressed by activated dendritic cells and stimulates proliferation of and interferon-g (IFN-g) production from memory Th1 CD4 þ T cells, suggesting an important function for this cytokine in the maintenance of Th1 immunity. 1 IL-23 also acts on dendritic cells to increase IL-12 production and the combination of IL-12 and IL-23 causes dendritic cells to secrete levels of IFN-g greater than either cytokine alone. 3 Furthermore, IL-23-treated dendritic cells pulsed with an otherwise poorly immunogenic peptide induced a CD4 þ /CD8 þ T-cell response in vivo. 3 Thus, IL-23 is capable of promoting a protective immune response to tumors and, similar to IL-12, may act at the interface of innate and adaptive immunities. 3 In addition, IL-23 is important in chronic inflammation, as IL-23 exposure can induce IL-17 production from activated CD4 þ T cells. 4 Multiple studies previously performed on various murine carcinoma establishment models have shown that stable expression of IL-23 in tumor lines results in decreased tumor growth, increased survival and ultimately tumor rejection with generation of antitumor immunity. [5] [6] [7] [8] [9] When engineered to stably express single chain IL-23, murine colon adenocarcinoma, melanoma and esophageal tumors exhibited regression and eventual rejection in mice. 5, 6 Tumor rejection due to expression of IL-23 coincided with the generation of a specific adaptive immune response and appears to be dependent on NK and T cells. [7] [8] [9] In addition, treatment with dendritic cells expressing IL-23, as well as systemic expression of this cytokine, resulted in inhibition of growth of preestablished tumors using mechanisms that appear to be T and NK cell dependent. 10, 11 However, the effects of local, intratumoral expression of IL-23 in a therapeutic cancer model have yet to be investigated.
Here we have examined the antitumor activity of adenovirally delivered IL-23 (Ad.IL-23) in a day-7 MCA205 murine fibrosarcoma tumor model. Multiple intratumoral injections of Ad.IL-23 resulted in a significant increase in survival time and complete rejection in 40% of tumors with subsequent generation of protective immunity and MCA205-specific cytotoxic T lymphocytes (CTLs). In addition, we have demonstrated that the antitumor activity of IL-23 is independent of IL-17, perforin and Fas ligand, but dependent on IFN-g and CD4 þ and CD8 þ T cells. Taken together, these results demonstrate that direct intratumoral injection of adenovirus expressing IL-23 results in enhanced survival, tumor eradication and generation of protective antitumor immunity. Thus, gene transfer of IL-23 could be an effective approach for inducing systemic, antitumor immunity following local, intratumor delivery.
Materials and methods

Adenoviruses
Adenovirus expressing IL-23 (Ad.IL-23) has been described previously. 12 Ad.IL-23 and Ad.Psi5 (empty vector) were prepared as follows: viruses were propagated on HEK-293 cells and purified by CsCl banding, followed by dialysis in 3% sucrose solution. Particle titer of purified viruses was determined by spectroscopy using the following equation: (OD 260 )(50)/9.09 Â 10 À13 . Infectious titers were determined using quantitative real-time PCR as previously described 13 and were approximately 100-fold less than particle titers. Viruses were aliquoted and stored at À80 1C until use. Relative IL-23 expression of each adenoviral preparation was analyzed by infecting 4 Â 10 4 MCA205 cells with increasing multiplicity of infections (MOIs) of Ad.IL-23 for 1 h at 37 1C/5% CO 2 in serum-free media. Complete medium was added and cells were then incubated for 72 h, after which the supernatants were harvested. IL-23 content was analyzed using the Ready-Set-Go IL-23 ELISA kit (eBioscience, San Diego, CA) following the manufacturer's instructions.
Animals
Female C57BL/6 and perforin, Fas ligand, IFN-g, CD4 þ and CD8 þ T-cell-deficient mice on a C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). The IL-17 receptor knockout mice are also on a C57BL/6 background, have been described previously. 14 Mice were used at 6-10 weeks of age. Animals were maintained under pathogen-free conditions at the Biotechnology Center Animal facility at the University of Pittsburgh. All procedures preformed were approved by the University of Pittsburgh Institutional Animal Care and Use Committee.
Cell lines MCA205 fibrosarcoma and YAC-1 cells (American Type
Culture Collection, Manassas, VA) were maintained in RPMI supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA) and L-glutamine (Gibco). Cells were kept in a humidified chamber at 37 1C/5% CO 2 and passaged every 2-3 days.
CTL assay
Two to three weeks after tumor resolution, cured mice were killed and spleens were harvested. Spleens were mechanically dissociated and treated with Red Cell Lysis buffer (Invitrogen) to remove all red blood cells.
Remaining lymphocytes were cultured with recombinant human IL-2 (R&D Systems, Minneapolis, MN) for 7 days before use in CTL assay. CTL assays were performed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, Madison, WI) following the manufacturer's instructions.
In vivo tumor studies For use in in vivo tumor experiments, confluent layers of MCA205 cells were dissociated by trypsin, washed three times with Hank's balanced salt solution (HBSS) (Gibco) and counted using Trypan blue exclusion. Mice were inoculated with 1 Â 10 5 MCA205 cells in 100 ml HBSS subcutaneously in the abdomen. On days 7, 9 and 11 after tumor inoculation, mice were injected intratumorally with 5 Â 10 10 particles (approximately 5 Â 10 8 plaqueforming units) of either Ad.Psi5 or Ad.IL-23. Tumor volume was monitored using a metric caliper until mice were killed due to excessive tumor size or tumor ulceration. Tumor-free or 'cured' mice were subject to tumor challenge 1-2 months after initial tumor resolution with 1 Â 10 5 MCA205 cells subcutaneously in the abdomen.
Statistics
Kaplan-Meier survival curves were plotted using SPSS version 16.0 (SPSS Inc, Chicago, IL). Mice were monitored until excessive tumor volume or tumor ulceration, at which time they were killed and recorded as occurrence of an event (death). Cured mice or those with tumors that did not warrant killing by the end of the experiment were censored. Tick marks on survival curves indicate times at which animals were censored. Log-rank tests of the survival curves provided P-values. Statistical analyses were two tailed, with a P-value less than 0.05 considered statistically significant.
Results
Production of IL-23 from Ad.IL-23-transduced MCA205 tumor cells To confirm IL-23 expression following Ad.IL-23mediated transduction of MCA205 fibrosarcoma tumor cells, 4 Â 10 4 MCA205 cells were infected with increasing MOIs of Ad.IL-23. Supernatants were harvested 72 h after adenoviral infection and analyzed for IL-23 expression by enzyme-linked immunosorbent assay (ELISA). As shown in Figure 1 , transduction of MCA205 cells with Ad.IL-23 resulted in release of IL-23 from the infected cells, but not from Ad.Psi5 or mock-infected cells. The biological activity of IL-23 produced by Ad.IL-23infected cells has been previously confirmed and published. 15 Intratumoral injections of Ad.IL-23 result in eradication of subcutaneous MCA205 tumors To examine the antitumor activity of Ad.IL-23, 6-to 8-week-old C57BL/6 mice were inoculated with 1 Â 10 5 MCA205 cells subcutaneously. On days 7, 9 and 11 post-tumor inoculation, mice were injected intratumorally with 5 Â 10 10 particles of Ad.IL-23 or Ad.Psi5 in 100 ml of saline. Mice treated with Ad.IL-23 exhibited a statistically significant increase in survival (P ¼ 0.000 versus empty vector control; Figure 2a ). In six experiments involving 40 mice treated with three injections of Ad.IL-23, treated mice showed decreased tumor volumes ( Figure 2c ) compared to empty vector controls and exhibited an overall tumor rejection rate of 40% ( Figure 2b) , with no evidence of cytokine-mediated toxicity. In addition, when mice bearing two MCA205 tumors were treated on days 7, 9 and 11 in only one tumor as described above, inhibition of tumor growth was observed in both injected and contralateral tumors, suggesting induction of a systemic antitumor response by IL-23 (data not shown). These results demonstrate that direct intratumoral injection of adenovirus expressing IL-23 increases survival, results in tumor rejection, and generates specific and protective antitumor immunity.
Given that three injections of Ad.IL-23 were highly effective in inducing antitumor immunity, we subsequently examined whether two or even one injection of Ad.IL-23 would be sufficient to mount an antitumor response. Established MCA205 tumors were injected intratumorally either twice (days 7 and 11) or once (day 7) with 5 Â 10 10 particles of Ad.IL-23. Treatment with two injections of Ad.IL-23 resulted in inhibition of tumor growth and tumor rejection in two of five mice (data not shown) whereas one treatment, while significantly increasing animal survival (Figure 2d ), did not result in tumor rejection in any animals (five mice total) (Figure 2e ). These results suggest that although even one dose of Ad.IL-23 can significantly increase the survival of tumor-bearing mice, multiple injections are necessary for maximal antitumor effect.
Ad.IL-23-mediated tumor rejection results in resistance to MCA205 challenge and generation of tumor-specific CTLs
To determine if Ad.IL-23-mediated tumor rejection led to generation of protective immunity, we challenged cured mice with 1 Â 10 5 MCA205s in the contralateral flank 10 weeks after tumor rejection. Naive mice were concurrently inoculated with MCA205s to confirm tumor take. Figure 3a shows two representative Ad.IL-23-treated, cured mice, challenged with MCA205s, as well as simultaneously inoculated naive mice. Overall, 'cured' mice remained tumor free for up to 3 months and all animals (eight mice total) challenged with a second dose of MCA205 cells were resistant to tumor development.
To determine if treatment of MCA205 tumors with Ad.IL-23 resulted in the generation of tumor-specific CTLs, spleens were harvested from Ad.IL-23-treated, tumor-free mice within 2-3 weeks of tumor resolution. Purified lymphocytes were cultured with rhIL-2 for 7 days and re-stimulated with MCA205 cells. CTL activity was measured by lactate dehydrogenase release from target cells. Cytotoxic activity was detected against MCA205 tumor cells, but not against YAC-1 (NK cell sensitive) cells ( Figure 3b ). The cytotoxic activity of splenocytes against MCA205, but not YAC-1, cells suggests that treatment of subcutaneous MCA205 tumors with Ad.IL-23 resulted in generation of antitumor immunity by production of MCA205-specific CTLs. This result is consistent with the ability of Ad.IL-23-treated, cured mice to resist MCA205 tumor challenge.
In addition, angiogenesis in tumors of mice treated with Ad.IL-23 was investigated. Tumors from Ad.IL-23treated mice were harvested and analyzed for CD31 by immunohistochemistry. Although not significant, a trend toward decreased angiogenesis was observed in Ad.IL-23treated animals versus controls (data not shown), suggesting that IL-23-mediated inhibition of angiogenesis is at least partially responsible for its antitumor activity.
IL-23 antitumor activity is independent of endogenous IL-17 production
The results above clearly demonstrate that adenoviralmediated, intratumoral delivery of IL-23 results in a significant antitumor response. To examine the nature of this immune response, we examined the ability of Ad.IL-23 to induce regression of MCA205 tumors in mice deficient for certain immunoregulatory molecules or cell types. In vivo, IL-23 strongly induces production of IL-17, 16 which has been previously shown to possess antitumor activity. 17 To determine if IL-23-mediated, endogenous IL-17 production may be responsible for the observed antitumor effects, we inoculated IL-17 receptordeficient mice with subcutaneous MCA205 tumors and treated with Ad.IL-23 on days 7, 9 and 11 post-tumor inoculation. IL-23 treatment significantly increased animal survival (P ¼ 0.047) compared to empty-vectortreated mice (Figure 4a ). In addition, 60% (three of five) of tumor-bearing mice experienced tumor resolution with kinetics similar to wild-type mice (Figure 4b ) and were resistant to tumor challenge. Taken together, these data Ad.Psi 5 Figure 2 Ad.IL-23 exhibits potent antitumor activity in the day-7 MCA205 fibrosarcoma tumor model. C57BL/6 mice (6-to 8-week old) were inoculated with 1 Â 10 5 MCA205 cells subcutaneously. Mice were injected intratumorally with 5 Â 10 10 particles of either Ad.IL-23 or Ad.Psi5 (empty vector) on days 7, 9 and 11 post-tumor inoculation. Tumor size was monitored using a metric caliper until tumor resolution or until animals were killed due to excessive ulceration or tumor size. Data are represented as animal survival using Kaplan-Meier survival curves (a), percent animals with tumors (b) and average tumor volume over time (c). Alternatively, mice were treated with a single injection of 5 Â 10 10 particles of Ad.IL-23 or Ad.Psi5 on day 7. Data are represented as animal survival and percent animals with tumors (d and e, respectively). Error bars represent ± standard error and asterisk (*) indicates that log-rank tests show that Ad.IL-23 treatment leads to a significant increase in survival compared to empty vector controls in mice treated both three times (P ¼ 0.000) and only once (P ¼ 0.007).
suggest that adenovirally delivered IL-23 antitumor activity is not mediated by endogenous IL-17 production.
IL-23 antitumor activity is independent of perforin
Perforin is produced by CD8 þ T cells and NK cells and is released on contact with the target cell to induce cell death. To determine if the antitumor activity of adenovirally delivered IL-23 is dependent on perforin-mediated lysis of tumor cells, we treated perforin-deficient mice with established MCA205 tumors with Ad.IL-23 as described above. Treatment with Ad.IL-23 resulted in a significant increase in survival (P ¼ 0.013; Figure 5a ), and led to tumor rejection in 30% of mice (3 of 10) (Figure 5b) . The cured perforin-deficient mice experienced tumor rejection in a similar time frame as cured, Ad.IL-23-treated wild-type mice and were resistant to tumor challenge (data not shown). These data suggest that adenovirally delivered IL-23 does not use performmediated killing as an antitumor effector mechanism.
IL-23 antitumor activity is independent of Fas ligand
Interactions between Fas and Fas ligand (FasL) are used by activated CD8 þ T cells and some CD4 þ effector cells to kill target cells through apoptosis. To determine if the antitumor activity of adenovirally delivered IL-23 requires Fas/Fas ligand interactions to eradicate tumor cells and generate antitumor immunity, we inoculated FasLdeficient mice with tumors and treated as described above. Interestingly, although Ad.IL-23 treatment did not lead to tumor rejection in any treated animals (10 total) (Figure 5d ), it did significantly increase survival compared to empty vector controls (P ¼ 0.000; Figure 5c ), leading us to conclude that IL-23 is able to function through a Fas/ FasL-independent mechanism to exert its antitumor effects. However, given that treatment did not result in eradication of tumors in any of the mice, it is also possible that at least part of the antitumor effect of IL-23 involves a Fas/FasL-dependent pathway.
IFN-g is necessary for IL-23 antitumor activity
Cytotoxic T lymphocytes and a subset of Th1 T cells secrete IFN-g on engagement of the T-cell receptor to exert their cytotoxic effects on target cells. To determine if IFN-g is necessary for the antitumor activity of adenovirally delivered IL-23, we treated IFN-g-deficient mice with established tumors as described above. Tumorbearing mice treated with Ad.IL-23 showed no significant increase in survival when compared to empty adenoviral vector controls (Figure 5e ). In addition, none of the treated mice completely rejected their tumor (0 of 10) (Figure 5f ), suggesting that adenovirally delivered IL-23 uses IFN-g as an effector mechanism to exert its antitumor effects.
Antitumor activity of IL-23 is dependent on the presence of CD4 þ T cells CD4 þ T cells have a variety of functions, including 'helping' the activation of CTLs and directly killing target cells, using mechanisms including Fas/FasL interactions and release of IFN-g. To determine if the antitumor activity of adenovirally delivered IL-23 is dependent on the presence of CD4 þ T cells, we inoculated CD4deficient mice with MCA205 tumors and treated with Ad.IL-23. Again, Ad.IL-23-treated mice showed no significant increase in survival when compared to empty adenoviral vector controls (Figure 6a ) and none rejected their tumor (10 animals total) ( Figure 6b ). These data suggest that adenovirally delivered IL-23 enhances the activity of CD4 þ T cells to exert optimal antitumor effects.
IL-23 uses CD8 þ T cells to exert its antitumor effects
Because IL-23 antitumor activity is dependent on IFN-g, a mechanism used by CD8 þ T cells to exert cytotoxic effects, it is possible that CD8 þ T cells are responsible for the antitumor effects of IL-23. Thus CD8 þ T-celldeficient mice were inoculated with MCA205 tumors and treated as described above. Interestingly, although treatment with Ad.IL-23 did lead to tumor rejection in 20% of animals (2 of 10) (Figure 6d ), IL-23 therapy did not significantly increase animal survival (Figure 6c ). This suggests that at least part of the antitumor effect of adenovirally delivered IL-23 is mediated through CD8 þ T-cell activity, in addition to other effector mechanisms that may be important in tumor elimination.
Discussion
The use of gene therapy for the treatment of cancer has been proven effective in many mouse cancer models and comprises the vast majority of human gene therapy clinical trials performed to date. 18 Here we have investigated the potential antitumor activity of the IL-12 family member IL-23. IL-23 is a relatively new member of the IL-12 family of heterodimeric cytokines and shares many immunostimulatory 1-3 and antitumor activities with IL-12. [19] [20] [21] [22] IL-23 has been shown to possess antitumor activity in the context of various establishment models of cancer [5] [6] [7] [8] [9] and to inhibit established tumor growth when overexpressed systemically or locally through dendritic cells. 10, 11 We chose to investigate the ability of adenovirally delivered IL-23 (Ad.IL-23) to inhibit tumor growth in a therapeutic mouse model of cancer for a number of reasons. First, systemic overexpression of immunostimulatory cytokines may be associated with toxicity, as is the case with systemically delivered IL-12. 22 In addition, as IL-23 is associated with a variety of autoimmune inflammatory diseases that are believed to be mediated at least in part by the generation of a specific subset of T cells that produce IL-17, 23 we hypothesized that local, rather than systemic, expression would reduce the risk of the unintentional development of any autoimmune pathology. Finally, expression of immunostimulatory cytokines within the tumor cells greatly increases the chances of generating an effective immune response against the tumor itself and is technically much simpler than transduction of any intermediate cell type.
Our results clearly demonstrate that treatment of day-7 MCA205 tumors with repeated intratumoral injections of Ad.IL-23 results in a significant increase in animal survival when compared to empty-vector-treated controls.
In six experiments involving 40 mice, Ad.IL-23-treated mice overall exhibited decreased tumor volume, with 40% of mice rejecting their tumors in about 25 days (Figures  2a-c) . The antitumor activity of IL-23 is consistent with previously published reports showing that stable expression of IL-23 in tumor cell lines leads to tumor rejection in tumor establishment models. [5] [6] [7] [8] [9] Although the overall cure rate in our experiments was slightly lower than was obtained in previous studies using establishment models (70% versus our 40%), this disparity is likely due to differences in the model. An established tumor is more difficult to eradicate than a tumor expressing IL-23 from the onset. In addition, differences in IL-23 expression levels in therapeutic versus establishment models may also ultimately affect the outcome, as it has been suggested that IL-23 expression levels may dictate whether IL-23 exhibits pro-or antitumor effects. 24 It is also necessary to note that while this article was in preparation, a paper demonstrating a prophylactic, but not therapeutic, effect of adenovirally delivered IL-23 in variety of murine tumors was published. 25 This disparity in results may be due to the use of different murine tumor models, use of a mutant form of p40 25 or initiating treatment at a different stage of the tumor model. In our studies, tumor-bearing mice were treated on days 7, 9 and 11 starting with an average tumor size of 4 mm compared to the studies performed in the previously mentioned paper, in which treatment was initiated when the average tumor volume reached 7 mm in diameter.
The tumor eradication rate of Ad.IL-23 also was dependent on the number of treatments, whereas enhancement of survival was not. Treating the established tumors with two or one injections of Ad.IL-23 (Figures 2d  and e ), the percent of mice with complete tumor regression was reduced, with three injections on alternate days generating the most optimal effects. However, treating mice either once or twice increased survival. We chose three separate injections of Ad.IL-23 as our treatment plan as it yielded both enhanced survival compared to controls and maximum tumor rejection rates. However, increased survival even at the lowest dose has therapeutic implications, as this suggests that use of low-dose Ad.IL-23 in combination with other Th1polarizing cytokines, such as IL-12, will provide even greater therapeutic response with minimal adenoviral-or cytokine-mediated toxicity.
Interestingly, all cured, Ad.IL-23-treated mice exhibited protective immunity on tumor challenge up to 3 months after rejection of the initial tumor (Figure 3a; data not shown). In contrast, only 56% (five of nine) of mice treated with adenovirus expressing IL-12 were resistant to tumor challenge (data not shown). This suggests that intratumoral, adenoviral delivery of IL-23 may activate a robust memory T-cell response and generate superior long-term protective immunity. Such results are promising in the context of using IL-23 in conjunction with IL-12, as presumably using IL-23 in combination with IL-12 will decrease the effective dose of IL-12 needed, hence reducing toxicity and increasing the duration of protective antitumor immunity.
IL-23 has been shown to induce IL-17 production by aiding the development of Th17 T cells. 16 Because IL-17 itself may possess antitumor activity, 17 we investigated whether the antitumor activity of IL-23 is mediated by endogenous IL-17 production. Using IL-17 receptordeficient mice, we demonstrated that the antitumor activity of IL-23 appears to be independent of endogenous IL-17 expression. IL-17 receptor-deficient mice treated with Ad.IL-23 exhibited increased survival and enhanced tumor rejection compared to animals treated with empty adenoviral vector (Figures 4a and b) . Thus, although IL-23 has been shown to be a potent activator of IL-17-producing cells, 4 in the context of adenovirally transduced tumor cells, either Th17 cells are not involved in the antitumor activity of IL-23 or the development of Th1 T cells is favored.
We next sought to determine the immune cell types involved in enacting IL-23-mediated antitumor activity. Tumor-bearing CD4 þ and CD8 þ T-cell-deficient mice treated with Ad.IL-23 exhibited no increase in survival compared to controls (Figures 6a and c) , indicating their requirement for IL-23 antitumor activity. It must be noted, however, that in two CD8 þ T-cell-deficient mice, Ad.IL-23 treatment led to tumor rejection, suggesting the involvement of other effector mechanisms in tumor eradication. To determine the effector mechanism(s) used by these cells, IFN-g-, perforin-and Fas-ligand-deficient, tumor-bearing mice were treated with Ad.IL-23. Mice deficient in IFN-g were completely refractory to IL-23 treatment (Figures 5e and f) , whereas mice deficient in perforin and Fas ligand exhibited increased survival and tumor rejection compared to controls (Figures 5a-d) . Cytotoxicity of splenocytes harvested from cured, wildtype animals demonstrate that tumor eradication was mediated, at least in part, by MCA205-specific CTLs (Figure 3b ), consistent with previous reports. 10, 11 Collectively, these data are consistent with previous results suggesting that the primary mechanism of IL-23 antitumor activity is CD4 þ T-cell-mediated activation of CD8 þ T cells to produce IFN-g. 10 Overall, our results demonstrate that adenoviral delivery of IL-23 into the tumor microenvironment of early stage tumors is therapeutic and able to generate protective immunity. Furthermore, our results show that the antitumor activity of IL-23 is independent of endogenous IL-17, perforin and, in part, FasL, but dependent on CD4 þ and CD8 þ T cells and IFN-g. Together, these data imply that tumor cell expression of IL-23 drives a Th1-type immune response, which is responsible for its antitumor activity. Our results indicate that direct adenoviral delivery of IL-23 into the tumor microenvironment to generate protective antitumor immunity is feasible and may posses clinical benefit when used either alone or in combination with other cytokines, such as IL-12.
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